Mannkind Corp (MNKD) 5.44 $MNKD
Too Good to Be True? Proceed With Caution on These 2 Biotechs
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Sat Mar 14, 11:02AM CDT
Tune in to this health care edition of Industry Focus for a look at two small biotechs that sound exciting -- and may in fact prove to be the next big thing -- but which currently face enough challenges that most Fools probably won't want to rush in....
OREX: 6.96 (-0.08), PTLA: 41.34 (+0.64), NVO: 48.88 (+1.28), VVUS: 2.99 (+0.17), SNY: 48.63 (+1.56), MNKD: 5.44 (-0.07), ARNA: 4.76 (-0.05)
A Look At Afrezza Prescriptions Through Week 6 And Predictions Through Week 10
Austin Moss - at Seeking Alpha - Fri Mar 13, 1:54PM CDT
MNKD: 5.44 (-0.07), SNY: 48.63 (+1.56)
Griffin Securities' Keith Markey Thinks These 5 Stocks Have Substantial Upside
Life Sciences Report - Seeking Alpha - Fri Mar 13, 9:10AM CDT
For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and efficacy, there's just no betting on a biotech stock. Over the last 25 years, Markey has seen nearly every type of...
SYN: 2.65 (-0.24), ZIOP: 13.12 (-0.20), UNIS: 3.52 (-0.20), FCSC: 5.29 (-0.10), XON: 45.63 (-0.86), MNKD: 5.44 (-0.07)
Interesting MNKD Put Options For May 1st
DividendChannel.com - Thu Mar 12, 10:54AM CDT
Investors in MannKind Corp saw new options become available today, for the May 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNKD options chain for the new May 1st contracts and identified the...
MNKD: 5.44 (-0.07)
Generex successful in increasing insulin concentration in spray product candidate
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 10:44AM CDT
MNKD: 5.44 (-0.07)
Coverage of Biotech Equities -- MannKind, Novavax, Curis, Pharmacyclics, and Alexion Pharma
PR Newswire - Tue Mar 10, 8:35AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRIS: 2.93 (-0.09), PCYC: 256.00 (+1.02), NVAX: 9.42 (+0.13), ALXN: 178.35 (+1.46), MNKD: 5.44 (-0.07)
A Close-Up Look At The Report That Had MannKind Investors Reeling
George Rho - at Seeking Alpha - Mon Mar 09, 11:36AM CDT
MNKD: 5.44 (-0.07)
Mannkind: Flawed? No Competition? Overall Superior Drug?
Looking For Diogenes - at Seeking Alpha - Mon Mar 09, 8:07AM CDT
MNKD: 5.44 (-0.07)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 4:42PM CST
VEEV: 25.04 (+0.18), NG: 3.03 (-0.10), CRIS: 2.93 (-0.09), EVTC: 22.09 (-0.15), GTN: 14.44 (+0.40), SM: 43.67 (+0.11), MNKD: 5.44 (-0.07), RIGL: 3.43 (-0.17), EXK: 1.77 (+0.08), WBAI: 11.83 (+0.23)
Seeking Alpha's Biotech Weekly: AbbVie - Pharmacyclitics, Orexigen Confusion, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Mar 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
PCYC: 256.00 (+1.02), MDT: 77.59 (+1.12), ARWR: 7.38 (-0.15), SPHS: 0.57 (+0.01), BSX: 17.34 (+0.73), MDVN: 129.97 (+1.30), JNJ: 100.73 (+1.52), AAC: 28.24 (+0.50), ABBV: 58.83 (+0.83), SNY: 48.63 (+1.56), SMMT: 10.81 (+0.11), ARNA: 4.76 (-0.05), XLRN: 41.20 (unch), MNK: 126.09 (+1.97), AQXP: 11.64 (-0.44), PFE: 34.44 (+0.44), AMGN: 161.80 (+7.54), GSK: 46.93 (+0.56), BMY: 67.83 (+0.96), MNKD: 5.44 (-0.07), CELG: 120.39 (+2.66), OREX: 6.96 (-0.08), PODD: 35.60 (+0.52), GERN: 4.15 (-0.19), TEVA: 60.63 (+0.63), TCON: 14.89 (+1.14), NVS: 97.92 (+0.88)
Technical Analysis of Wal-Mart, Coca-Cola, MannKind and Las Vegas Sands
Kumar Abhishek - Amigobulls - Thu Mar 05, 7:02AM CST
Coca-Cola stock price has again found support at 100 day SMA. The 100 day SMA has provided support to coca cola stock price on multiple occasions.
KO: 40.15 (+0.24), WMT: 83.19 (+1.29), LVS: 52.98 (+0.61), MNKD: 5.44 (-0.07)
5 Things MannKind Corporation's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Thu Mar 05, 6:21AM CST
MannKind 's fourth-quarter conference was only 31 minutes long, but the call contained some tidbits of insight from the biotech's management that investors should know. Source: MannKind. "In fact, we were just, the other day, asked if we...
SNY: 48.63 (+1.56), MNKD: 5.44 (-0.07)
MannKind: Use This Drop As An Opportunity
Kumquat Research - at Seeking Alpha - Wed Mar 04, 7:33AM CST
MNKD: 5.44 (-0.07)
MannKind's Charts Suggest Waiting on the Stock After Goldman's Downgrade
at The Street - Tue Mar 03, 3:22PM CST
Here's a technical look at the stock after a brutal downgrade.
MNKD: 5.44 (-0.07)
New Buy Ins And Profit Taking: The Well-Valued Growth Portfolio This Month
Psycho Analyst - at Seeking Alpha - Tue Mar 03, 1:05PM CST
ODFL: 79.32 (+1.13), ESRX: 83.44 (+2.07), THO: 62.03 (+0.37), SWKS: 96.15 (+3.23), LGIH: 14.49 (-0.10), LKQ: 24.56 (+0.14), DG: 75.38 (+1.08), MNKD: 5.44 (-0.07), LUV: 45.28 (+0.77)
Why MannKind Corp. Stock Crashed Today
George Budwell, The Motley Fool - Motley Fool - Tue Mar 03, 10:48AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of MannKind Corp. fell by more than 14% on...
GS: 192.03 (+2.69), SNY: 48.63 (+1.56), MNKD: 5.44 (-0.07)
Potential Afrezza discounts and challenging competitive landscape behind Goldman downgrade of MannKind
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 10:46AM CST
LLY: 71.08 (+1.19), SNY: 48.63 (+1.56), MNKD: 5.44 (-0.07)
Cramer: Goldman's Negative MannKind Report Creates 'Problematic Situation'
at The Street - Tue Mar 03, 10:28AM CST
Cramer says the negative Goldman Sachs is having an unhealthy effect on MannKind's stock.
MNKD: 5.44 (-0.07)
Forget Biased Analysts, Diabetics Love MannKind's Afrezza
Maredin Capital Advisors - Seeking Alpha - Tue Mar 03, 9:32AM CST
The MannKind (ticker " MNKD "
story/plot continues to thicken Over the past several years, investors, both long and short, have had to rely on trial data, and the opinions of analysts to guide their investment decisions. This led to a...
MNKD: 5.44 (-0.07)
MannKind off 10% premarket on Goldman downgrade
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:24AM CST
MNKD: 5.44 (-0.07)
Too Good to Be True? Proceed With Caution on These 2 Biotechs
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Sat Mar 14, 11:02AM CDT
Tune in to this health care edition of Industry Focus for a look at two small biotechs that sound exciting -- and may in fact prove to be the next big thing -- but which currently face enough challenges that most Fools probably won't want to rush in....
OREX: 6.96 (-0.08), PTLA: 41.34 (+0.64), NVO: 48.88 (+1.28), VVUS: 2.99 (+0.17), SNY: 48.63 (+1.56), MNKD: 5.44 (-0.07), ARNA: 4.76 (-0.05)
A Look At Afrezza Prescriptions Through Week 6 And Predictions Through Week 10
Austin Moss - at Seeking Alpha - Fri Mar 13, 1:54PM CDT
MNKD: 5.44 (-0.07), SNY: 48.63 (+1.56)
Griffin Securities' Keith Markey Thinks These 5 Stocks Have Substantial Upside
Life Sciences Report - Seeking Alpha - Fri Mar 13, 9:10AM CDT
For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and efficacy, there's just no betting on a biotech stock. Over the last 25 years, Markey has seen nearly every type of...
SYN: 2.65 (-0.24), ZIOP: 13.12 (-0.20), UNIS: 3.52 (-0.20), FCSC: 5.29 (-0.10), XON: 45.63 (-0.86), MNKD: 5.44 (-0.07)
Interesting MNKD Put Options For May 1st
DividendChannel.com - Thu Mar 12, 10:54AM CDT
Investors in MannKind Corp saw new options become available today, for the May 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNKD options chain for the new May 1st contracts and identified the...
MNKD: 5.44 (-0.07)
Generex successful in increasing insulin concentration in spray product candidate
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 10:44AM CDT
MNKD: 5.44 (-0.07)
Coverage of Biotech Equities -- MannKind, Novavax, Curis, Pharmacyclics, and Alexion Pharma
PR Newswire - Tue Mar 10, 8:35AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRIS: 2.93 (-0.09), PCYC: 256.00 (+1.02), NVAX: 9.42 (+0.13), ALXN: 178.35 (+1.46), MNKD: 5.44 (-0.07)
A Close-Up Look At The Report That Had MannKind Investors Reeling
George Rho - at Seeking Alpha - Mon Mar 09, 11:36AM CDT
MNKD: 5.44 (-0.07)
Mannkind: Flawed? No Competition? Overall Superior Drug?
Looking For Diogenes - at Seeking Alpha - Mon Mar 09, 8:07AM CDT
MNKD: 5.44 (-0.07)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 4:42PM CST
VEEV: 25.04 (+0.18), NG: 3.03 (-0.10), CRIS: 2.93 (-0.09), EVTC: 22.09 (-0.15), GTN: 14.44 (+0.40), SM: 43.67 (+0.11), MNKD: 5.44 (-0.07), RIGL: 3.43 (-0.17), EXK: 1.77 (+0.08), WBAI: 11.83 (+0.23)
Seeking Alpha's Biotech Weekly: AbbVie - Pharmacyclitics, Orexigen Confusion, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Mar 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
PCYC: 256.00 (+1.02), MDT: 77.59 (+1.12), ARWR: 7.38 (-0.15), SPHS: 0.57 (+0.01), BSX: 17.34 (+0.73), MDVN: 129.97 (+1.30), JNJ: 100.73 (+1.52), AAC: 28.24 (+0.50), ABBV: 58.83 (+0.83), SNY: 48.63 (+1.56), SMMT: 10.81 (+0.11), ARNA: 4.76 (-0.05), XLRN: 41.20 (unch), MNK: 126.09 (+1.97), AQXP: 11.64 (-0.44), PFE: 34.44 (+0.44), AMGN: 161.80 (+7.54), GSK: 46.93 (+0.56), BMY: 67.83 (+0.96), MNKD: 5.44 (-0.07), CELG: 120.39 (+2.66), OREX: 6.96 (-0.08), PODD: 35.60 (+0.52), GERN: 4.15 (-0.19), TEVA: 60.63 (+0.63), TCON: 14.89 (+1.14), NVS: 97.92 (+0.88)
Technical Analysis of Wal-Mart, Coca-Cola, MannKind and Las Vegas Sands
Kumar Abhishek - Amigobulls - Thu Mar 05, 7:02AM CST
Coca-Cola stock price has again found support at 100 day SMA. The 100 day SMA has provided support to coca cola stock price on multiple occasions.
KO: 40.15 (+0.24), WMT: 83.19 (+1.29), LVS: 52.98 (+0.61), MNKD: 5.44 (-0.07)
5 Things MannKind Corporation's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Thu Mar 05, 6:21AM CST
MannKind 's fourth-quarter conference was only 31 minutes long, but the call contained some tidbits of insight from the biotech's management that investors should know. Source: MannKind. "In fact, we were just, the other day, asked if we...
SNY: 48.63 (+1.56), MNKD: 5.44 (-0.07)
MannKind: Use This Drop As An Opportunity
Kumquat Research - at Seeking Alpha - Wed Mar 04, 7:33AM CST
MNKD: 5.44 (-0.07)
MannKind's Charts Suggest Waiting on the Stock After Goldman's Downgrade
at The Street - Tue Mar 03, 3:22PM CST
Here's a technical look at the stock after a brutal downgrade.
MNKD: 5.44 (-0.07)
New Buy Ins And Profit Taking: The Well-Valued Growth Portfolio This Month
Psycho Analyst - at Seeking Alpha - Tue Mar 03, 1:05PM CST
ODFL: 79.32 (+1.13), ESRX: 83.44 (+2.07), THO: 62.03 (+0.37), SWKS: 96.15 (+3.23), LGIH: 14.49 (-0.10), LKQ: 24.56 (+0.14), DG: 75.38 (+1.08), MNKD: 5.44 (-0.07), LUV: 45.28 (+0.77)
Why MannKind Corp. Stock Crashed Today
George Budwell, The Motley Fool - Motley Fool - Tue Mar 03, 10:48AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of MannKind Corp. fell by more than 14% on...
GS: 192.03 (+2.69), SNY: 48.63 (+1.56), MNKD: 5.44 (-0.07)
Potential Afrezza discounts and challenging competitive landscape behind Goldman downgrade of MannKind
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 10:46AM CST
LLY: 71.08 (+1.19), SNY: 48.63 (+1.56), MNKD: 5.44 (-0.07)
Cramer: Goldman's Negative MannKind Report Creates 'Problematic Situation'
at The Street - Tue Mar 03, 10:28AM CST
Cramer says the negative Goldman Sachs is having an unhealthy effect on MannKind's stock.
MNKD: 5.44 (-0.07)
Forget Biased Analysts, Diabetics Love MannKind's Afrezza
Maredin Capital Advisors - Seeking Alpha - Tue Mar 03, 9:32AM CST
The MannKind (ticker " MNKD "
story/plot continues to thicken Over the past several years, investors, both long and short, have had to rely on trial data, and the opinions of analysts to guide their investment decisions. This led to a... MNKD: 5.44 (-0.07)
MannKind off 10% premarket on Goldman downgrade
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:24AM CST
MNKD: 5.44 (-0.07)
